ARTICLE | Clinical News
SIG990: Phase I data
October 3, 2016 7:00 AM UTC
Top-line data from an open-label, U.S. Phase I trial in patients with acne rosacea showed that twice-daily topical DMT210 for 28 days was well tolerated and reduced erythema and lesion counts. This ye...